Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide

Clinical Breast Cancer

Volumn 7, Issue 3, 2006, Pages 237-243

  Kelly, Hanna ^a   Kimmick, Gretchen ^b   Dees, Claire ^a   Collichio, Frances ^a   Gatti, Lisa ^c   Sawyer, Lynda ^c   Ivanova, Anastasia ^d   Dressler, Lynn ^c   Graham, Mark L ^a   Carey, Lisa A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d IL   (United States)

Author keywords

Adjuvant therapy; Chemotherapy

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART ATRIUM FIBRILLATION; HEART EDEMA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MYALGIA; PATIENT DECISION MAKING; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; SIDE EFFECT; TREATMENT DURATION;

EID: 33748990291     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.035     Document Type: Article

References (18)

1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672.
2. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.
3. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-2685.
4. Cance WG, Carey LA, Calvo BF, et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 2002; 236:295-302; discussion 303.
5. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17:460-469.
6. Carey LA, Metzger R, Dees EC, et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 2005; 97:1137-1142.
7. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23:3676-3685.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
9. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23:7820-7826.
10. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorabicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003; 21:46-53.
11. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of basal-like breast cancer phenotype. Breast Cancer Res Treat 2004; 88(suppl 1):S48 (Abstract #1023).
12. Berry D, Cirrincione C, Henderson I, et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive breast cancer: 20-year experience of the CALGB and US breast intergroup. Breast Cancer Res Treat 2004; 88(suppl 1):S17 (Abstract #29).
13. Geisler S, Lonning PE, Ass T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61:2505-2512.
14. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11:5678-5685.
15. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6:50-56.
16. Bertheau P, Plassa F, Espie M, et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002; 360:852-854.
17. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869-10874.
18. Greenblatt MS, Chappuis PO, Bond JP et al. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 2001; 61:4092-4097.